Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus MINOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus MINOCIN.
ACTICLATE CAP vs MINOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
100 mg orally or intravenously every 12 hours for 24 hours, then 100 mg every 12 hours; severe infections: 200 mg initially, then 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life is 11–17 hours in patients with normal renal function; prolonged up to 18–69 hours in renal impairment.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Primarily renal (approximately 70% unchanged) and biliary/fecal (approximately 30%, with enterohepatic recycling).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic